Literature DB >> 9371983

Erythrocyte dehydration in pathophysiology and treatment of sickle cell disease.

C Brugnara1.   

Abstract

A prominent feature of sickle cell disease is the presence of cells with markedly increased sickle cell hemoglobin concentration, as a consequence of the loss of potassium, chloride, and water from the erythrocyte. Because of the extreme dependency of the kinetic of polymerization on sickle cell hemoglobin concentration, these dehydrated erythrocytes have an increased tendency to polymerize and sickle. Thus blockade of the loss of potassium from the erythrocyte should prevent the increase in sickle cell hemoglobin concentration and reduce sickling. The availability of this potential therapeutic option is based on a detailed knowledge of the mechanisms leading to cell dehydration. Two ion transport pathways, the K-Cl cotransport and the Ca(2+)-activated K+ channel, play a prominent role in the dehydration of sickle erythrocytes. Possible therapeutic strategies include inhibition of K-Cl cotransport by increasing erythrocyte Mg2+ content and inhibition of the Ca(2+)-activated K channel by oral administration of clotrimazole.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 9371983     DOI: 10.1097/00062752-199502020-00005

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  14 in total

1.  (39)K nuclear magnetic resonance and a mathematical model of K(+) transport in human erythrocytes.

Authors:  Anthony D Maher; Bogdan E Chapman; Philip W Kuchel
Journal:  Eur Biophys J       Date:  2005-12-10       Impact factor: 1.733

Review 2.  Regulation of K-Cl cotransport: from function to genes.

Authors:  N C Adragna; M Di Fulvio; P K Lauf
Journal:  J Membr Biol       Date:  2004-10-01       Impact factor: 1.843

3.  Faster Sickling Kinetics and Sickle Cell Shape Evolution during Repeated Deoxygenation and Oxygenation Cycles.

Authors:  E Du; M Dao
Journal:  Exp Mech       Date:  2018-11-28       Impact factor: 2.808

4.  Kinetics of sickle cell biorheology and implications for painful vasoocclusive crisis.

Authors:  E Du; Monica Diez-Silva; Gregory J Kato; Ming Dao; Subra Suresh
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-20       Impact factor: 11.205

Review 5.  Fluid replacement therapy for acute episodes of pain in people with sickle cell disease.

Authors:  Uduak Okomo; Martin M Meremikwu
Journal:  Cochrane Database Syst Rev       Date:  2017-07-31

6.  Common PIEZO1 Allele in African Populations Causes RBC Dehydration and Attenuates Plasmodium Infection.

Authors:  Shang Ma; Stuart Cahalan; Gregory LaMonte; Nathan D Grubaugh; Weizheng Zeng; Swetha E Murthy; Emma Paytas; Ramya Gamini; Viktor Lukacs; Tess Whitwam; Meaghan Loud; Rakhee Lohia; Laurence Berry; Shahid M Khan; Chris J Janse; Michael Bandell; Christian Schmedt; Kai Wengelnik; Andrew I Su; Eric Honore; Elizabeth A Winzeler; Kristian G Andersen; Ardem Patapoutian
Journal:  Cell       Date:  2018-03-22       Impact factor: 41.582

Review 7.  Headache and Facial Pain in Sickle Cell Disease.

Authors:  Angeliki Vgontzas; Larry Charleston; Matthew S Robbins
Journal:  Curr Pain Headache Rep       Date:  2016-03

Review 8.  Triterpenoid inducers of Nrf2 signaling as potential therapeutic agents in sickle cell disease: a review.

Authors:  Amma Owusu-Ansah; Sung Hee Choi; Agne Petrosiute; John J Letterio; Alex Yee-Chen Huang
Journal:  Front Med       Date:  2014-12-15       Impact factor: 4.592

9.  Magnesium for treating sickle cell disease.

Authors:  Nan Nitra Than; Htoo Htoo Kyaw Soe; Senthil K Palaniappan; Adinegara Bl Abas; Lucia De Franceschi
Journal:  Cochrane Database Syst Rev       Date:  2019-09-09

10.  Drugs for preventing red blood cell dehydration in people with sickle cell disease.

Authors:  Srikanth Nagalla; Samir K Ballas
Journal:  Cochrane Database Syst Rev       Date:  2018-10-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.